These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

695 related items for PubMed ID: 16931170

  • 1. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA, Villela R, Silverberg MS, Greenberg GR.
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
    [Abstract] [Full Text] [Related]

  • 2. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 3. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
    Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB.
    Gastrointest Endosc; 2006 Mar; 63(3):433-42; quiz 464. PubMed ID: 16500392
    [Abstract] [Full Text] [Related]

  • 4. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 5. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.
    N Engl J Med; 2003 Feb 13; 348(7):601-8. PubMed ID: 12584368
    [Abstract] [Full Text] [Related]

  • 6. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.
    Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P.
    Gastroenterology; 2009 Nov 13; 137(5):1628-40. PubMed ID: 19664627
    [Abstract] [Full Text] [Related]

  • 7. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q, Hogezand RA, Lamers CB, Verspaget HW.
    Aliment Pharmacol Ther; 2004 Sep 01; 20(5):585-92. PubMed ID: 15339330
    [Abstract] [Full Text] [Related]

  • 8. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.
    Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P.
    Gastroenterology; 2003 Apr 01; 124(4):917-24. PubMed ID: 12671888
    [Abstract] [Full Text] [Related]

  • 9. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    Domènech E, Hinojosa J, Nos P, Garcia-Planella E, Cabré E, Bernal I, Gassull MA.
    Aliment Pharmacol Ther; 2005 Dec 01; 22(11-12):1107-13. PubMed ID: 16305724
    [Abstract] [Full Text] [Related]

  • 10. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
    Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel JF, Lemann M, Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives.
    Gastroenterology; 2012 Jan 01; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
    [Abstract] [Full Text] [Related]

  • 11. Infliximab treatment for symptomatic Crohn's disease strictures.
    Pelletier AL, Kalisazan B, Wienckiewicz J, Bouarioua N, Soulé JC.
    Aliment Pharmacol Ther; 2009 Feb 01; 29(3):279-85. PubMed ID: 19035967
    [Abstract] [Full Text] [Related]

  • 12. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
    Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD.
    Dis Colon Rectum; 2006 Dec 01; 49(12):1837-41. PubMed ID: 17041753
    [Abstract] [Full Text] [Related]

  • 13. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
    Miheller P, Muzes G, Zágoni T, Tóth M, Rácz K, Tulassay Z.
    Orv Hetil; 2005 Jul 10; 146(28):1477-80. PubMed ID: 16130441
    [Abstract] [Full Text] [Related]

  • 14. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.
    Drobne D, Bossuyt P, Breynaert C, Cattaert T, Vande Casteele N, Compernolle G, Jürgens M, Ferrante M, Ballet V, Wollants WJ, Cleynen I, Van Steen K, Gils A, Rutgeerts P, Vermeire S, Van Assche G.
    Clin Gastroenterol Hepatol; 2015 Mar 10; 13(3):514-521.e4. PubMed ID: 25066841
    [Abstract] [Full Text] [Related]

  • 15. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease.
    Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA.
    Scand J Gastroenterol; 2011 Mar 10; 46(3):310-8. PubMed ID: 21087119
    [Abstract] [Full Text] [Related]

  • 16. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery.
    Kane S, Ford J, Cohen R, Wagner C.
    J Clin Gastroenterol; 2009 Aug 10; 43(7):613-6. PubMed ID: 19142167
    [Abstract] [Full Text] [Related]

  • 17. Infliximab in the surgical management of complex fistulating anal Crohn's disease.
    Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D.
    Colorectal Dis; 2005 Mar 10; 7(2):164-8. PubMed ID: 15720356
    [Abstract] [Full Text] [Related]

  • 18. [Treatment of Crohn's disease by infliximab. About 20 cases].
    Serghini M, Karoui S, Meknini M, Matri S, Kallel L, Fekih M, Boubaker J, Filali A.
    Tunis Med; 2009 Sep 10; 87(9):579-82. PubMed ID: 20180377
    [Abstract] [Full Text] [Related]

  • 19. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F.
    Scand J Gastroenterol; 2006 Sep 10; 41(9):1064-72. PubMed ID: 16938720
    [Abstract] [Full Text] [Related]

  • 20. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J, López-Larrea C, González S, Fuentes D, Dieguez A, Deschamps EM, Pérez-Pariente JM, López-Vázquez A, de Francisco R, Rodrigo L.
    Am J Gastroenterol; 2002 Sep 10; 97(9):2350-6. PubMed ID: 12358255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.